Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial — Shukui Qin (2023) | RDL Network
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Peter R. Galle, Richard S. Finn, Shukui Qin, Masafumi Ikeda, Andrew X. Zhu, Tae‐You Kim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Sohail Mulla, Wendy Verret, Derek-Zhen Xu, Sairy Hernandez, Beiying Ding, Juan Liu, Chen Huang, Ho Yeong Lim, Ann‐Lii Cheng, Michel Ducreux
Thomas Yau, Joong‐Won Park, Richard S. Finn, Ann‐Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J. Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Éric Assenat, Renata Zaucha, Junji Furuse, Ghassan K. Abou‐Alfa, Anthony B. El-Khoueiry, Ignacio Melero, Damir Begic,
Thomas Yau, Peter R. Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Jean–Frédéric Blanc, Joong‐Won Park, Edward Gane, Matthias Pinter, Ana Matilla Peña, Masafumi Ikeda, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Hong Jae Chon, Joanna Wójcik-Tomaszewska, Gontran Verset,
Sylvie Bonvalot, Alessandro Gronchi, C. Le Péchoux, Carol J. Swallow, D. Strauß, Pierre Méeus, Frits van Coevorden, Stephan Stoldt, Eberhard Stoeckle, Piotr Rutkowski, Marco Rastrelli, Chandrajit P. Raut, Daphne Hompes, Antonino De Paoli, Claudia Sangalli, Charles Honoré, Peter Chung, Aisha Miah, Jean Yves Blay, Marco Fiore, Jean‐Jacques Stelmes,
Discussion(0)
No comments yet. Be the first to comment.